Albright Partners

CEO exits at an all time high in the US - also within Health Care. https://lnkd.in/dbK4qMz2

Season Greetings from all of us at Albright to all of you: Our fabulous clients, candidates and partners🎄

Teaser: Looking forward to our January release of Albright's latest study report. #danishlifesciences #pharma #medtech #biotech

🌍Week 50: Top news in Pharma, Biotech & Medtech🌍   1️⃣ Bavarian Nordic is closing down R&D site in San Diego.    Bavarian Nordic is closing its R&D department in San Diego whixh it took over when acquiring Emergent Biosolutions' vaccine portfolio. (Read more: https://lnkd.in/dvDgbNUy)      2️⃣Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery.                                          The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million from a syndicate of nearly 20 investors. (Read more: https://lnkd.in/d_-vRwZF)      3️⃣Intuitive´s da Vinci beats non-robotic surgeries in cancer meta-analysis.                          Rates of postoperative complications, readmissions and death were lower after robotic surgeries than laparoscopic and open procedures. (Read more: https://lnkd.in/g8YChbmU)         4️⃣Endometriosis drug research, long underfunded, confronts familiar problems in women´s health. Up to 10% of women globally have endometriosis, yet the often misunderstood disease largely remains off of drugmakers’ radar screens. (Read more: https://lnkd.in/dH-uMpPA) 5️⃣ How Trump´s second term will affect the medtech industry.                From M&A and tariffs to new health leaders, here are the top issues for the medtech industry to watch when President-elect Donald Trump returns to office. (Read more: https://lnkd.in/daQGsx-h)   6️ Dimension gets $500M to bankroll biotech´s convergence with tech.                         GE The firm’s co-founders claim to be pursuing a “contrarian” approach, building a team equally versed in both computing and life sciences.           (Read more: https://lnkd.in/dkguHUqB)       7️⃣ Patterson, a dental products distributor, agrees to $4.1B sale to healthcare investor.   Last week, Patterson Companies announced it would seek strategic alternatives after the company’s profit decreased by one-third in its fiscal second quarter. (Read more: https://lnkd.in/g-jdBhq8)       8️⃣ Gene therapy uptake in sickle cell stays slow, despite patient interest.                                  A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of Casgevy and Lyfgenia during their first year on market. (Read more: https://lnkd.in/dzjKvkF5)   

🌍Week 49: Top news in Pharma, Biotech & Medtech🌍   1️⃣ Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives.   The company has raised $84 million to advance a so-called GIP antagonist into clinical testing for weight loss. (Read more: https://lnkd.in/eJvAwBJH)     2️⃣ FDA issues final guidance on postmarket updates to AI-enabled devices.                                           By using pre-determined change control plans, manufacturers can update AI-enabled devices without filing an additional FDA submission. (Read more: https://lnkd.in/giuSNyQY)     3️⃣Diabetes advocacy group discourages use of compounded GLP-1 drugs.                           The American Diabetes Association recommended doctors prescribe alternative FDA-approved drugs as Wegovy and Zepbound remain difficult to reliably obtain. (Read more: https://lnkd.in/d_jgf9sZ)       4️⃣Haemonetics to offload whole-blood business for up to $67M.                                             Selling the assets to Italy’s GVS should help Haemonetics improve its revenue growth and profit margins, analysts said. (Read more: https://lnkd.in/dKerdJxp) 5️⃣ Novartis wagers billions of dollars on PTC Huntington´s drug.                    At the center of a new licensing deal is an experimental medicine currently being tested in a roughly 250-person study that should produce results next year.  (Read more: https://lnkd.in/dXrM-ZzA) 6️⃣   GE Healthcare to buy radiopharmaceutical firm Nihon Medi-Physics.                        GE Healthcare has identified radiopharmaceuticals as a growth driver for the company and Japan as a key market. (Read more: https://lnkd.in/gRJrFbJu)      7️⃣ Janux impresses Wall Street with new prostate cancer drug results. While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said. (Read more: https://lnkd.in/dk245b2W)      8️⃣ Movano receives FDA nod for smart ring´s pulse oximeter feature.    Movano Health plans to market the Evie Ring to organizations that run clinical trials and healthcare companies that are helping patients manage chronic diseases. (Read more: https://lnkd.in/gmwBRdxR)  

On behalf of our client - a global biotech company - we are conducting an executive search for a Senior Director, QA GCP. #gcp #gvp #glp #biotech #pharma #biopharma #clinical https://lnkd.in/dYQSNgwN

On behalf of our client - a highly successful Animal Health company - we are conducting an executive search for a Nordic Business Unit Head, Companion Animals. #animalhealth #companionanimals #pets #vets #rx https://lnkd.in/dzvGqqHW

"Hjemmearbejde er på en måde et gode, som medarbejderne har vænnet sig til, og måske nu tager for givet, men som nu gradvist bliver udfordret. Jeg ved, at nogle HR-afdelinger – jfr. Albright's seneste HR studie – føler sig presset på retention og rekruttering som følge af den større on-site forventning arbejdsgiverne har til deres medarbejdere. Dette forstærkes yderligere af, at efterspørgsel efter medarbejdere i sektoren langt overstiger udbuddet på de fleste funktionsområder." -Henrik Brabrand, Adm. Direktør, Albright Partners A/S Læs mere om studier her: https://lnkd.in/dr_-zN6k #hjemmearbejde #hybridwork https://lnkd.in/dtjDTaqp

🌍Week 48: Top news in Global and Danish Pharma, Biotech & Medtech🌍   1️⃣ Amgen obesity drug cuts weight in study, but results miss Wall Street´s high mark.  The drugmaker is planning Phase 3 trials of its medicine MariTide that will include people with heart disease and other obesity-related conditions. (Read more: https://lnkd.in/gRtDBdYy)   2️⃣ Embecta discontinues insulin patch pump development.                                         CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” (Read more: https://lnkd.in/gR6hc93U)   3️⃣New data could help Merck expand use of cardiovascular drug.                          Positive results from a study of Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent expirations this decade. (Read more: https://lnkd.in/dczpvjAd)  4️⃣ Lundbeck-topchef: Sidste hurdle er fjernet i opkøb af Longboard. Lundbeck har indfriet betingelserne for opkøbet af amerikanske Longboard Pharmaceuticals, og med et ejerskab på 88,6 pct. af aktierne gør Lundbeck nu klar til at afnotere selskabet i USA. (Read more: https://lnkd.in/dcZdW_KR)   5️⃣ Roche´s TIGIT-targeting drug for cancer fails its biggest test.                                         Results showed that adding tiragolumab to Roche’s immunotherapy Tecentriq did not extend survival in a closely followed Phase 3 study called SKYSCRAPER-01. (Read more: https://lnkd.in/d6QtywXb) 6️⃣   Flere og bedre investeringer I life science – nyt netværk skal gøre investorer klogere på life science-området.                                                               Danish Life Science Cluster overtager netværket Life Science Invest, som arbejder for at tiltrække flere og stærkere investeringer på life science-området. Netværket har I 2024 engageret flere end 250 deltagere i forsøget på at modne investorer og vejlede om funding inden for healthtech, medtech og biotech.  (Read more: https://lnkd.in/dYgBJ64s)     7️⃣ Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.                                                                                                                                (Read more: https://lnkd.in/geTndYSc)  

About 1 in 4 consumers do not think they have access to high-quality care acc. to Deloitte study.    #2025outlook #uslifesciences #healthcare   https://lnkd.in/dJDmQbpf